On February 13, 2025, the FDA approved Samsung Bioepis Co., Ltd.’s denosumab biosimilars, OSPOMYV™ (denosumab-dssb; 60 mg pre-filled syringe) ...
The MoU combines HMRI and the University of Newcastle's research expertise with Novartis' medical solutions leadership. It ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback